GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

Journal

GLP-1 and Tirzepatide Journal

Direct answer

The journal covers the things moving fastest in this market: compounding regulation, pricing practice and clinical evidence. Each piece is built on primary sources and says what the evidence does not establish. The two newest, published November 21, 2026, check NexLife’s plan terms and explain switching from semaglutide to tirzepatide.

Answer last reviewed:

New this month

What this section is for

The rest of this site answers stable questions — what a drug costs, what a trial found, how to verify a pharmacy. The journal covers what is changing, which in this market is a great deal.

The single largest story is regulatory. The FDA’s April 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list would close the last pathway permitting large-scale compounding of these molecules. The comment period closed on July 30, 2026, and no final decision had been published as of October 15, 2026.

The second is commercial. Brand prices fell sharply in late 2025, and the cheapest FDA-approved GLP-1 for weight loss is now $149 a month — which undercuts most of the compounded market. Almost no comparison page has updated.

How these pieces are built

Every article cites the primary source: the agency's own notice, the registry entry, the peer-reviewed paper, or the provider's own page captured on a date. A news article about a study is not a source for that study's results.

Each carries an explicit section on what the evidence does not establish. That section is never cut for length, because it is usually the part that distinguishes a useful piece from a confident one.

Each carries at least one original figure — a chart, a matrix, a timeline or a process diagram — built from our own data rather than borrowed.

What we have not published, and why

Pieces that are not ready stay unpublished until their figures are confirmed against primary sources.

The retatrutide phase 3 piece is the notable one. Figures circulating online — 28.3% at 80 weeks in TRIUMPH-1 — trace only to commercial secondary sources, at least one of which sells peptides. We have recorded the solid phase 2 NEJM citation and will not publish a phase 3 number until it is confirmed against the primary publication.

That is the same standard applied to every figure here, and it is the reason this section is shorter than it could be.

Journal status
Published — 20 (100%)Commissioned, unwritten — 0 (0%)20records
Show this figure as a table
Data table
StatusRecordsShare
Published20100%
Commissioned, unwritten00%
How tirzepatide compounding became a regulatory question
2022Tirzepatide added to the F2024-10FDA declared the tirzepati2025-02FDA declared the semagluti2025-09-16FDA issued 55+ warning let2026-02-09Novo Nordisk sued Hims & H2026-03-03FDA released 30 further wa2026-03-09Hims & Hers settled with N2026-04-30FDA proposed excluding tir2026-05-01Formal notice published at2026-06-26Comment period extended to2026-07-30Comment period closes
Show this figure as a table
Data table
DateEvent
2022Tirzepatide added to the F
2024-10FDA declared the tirzepati
2025-02FDA declared the semagluti
2025-09-16FDA issued 55+ warning let
2026-02-09Novo Nordisk sued Hims & H
2026-03-03FDA released 30 further wa
2026-03-09Hims & Hers settled with N
2026-04-30FDA proposed excluding tir
2026-05-01Formal notice published at
2026-06-26Comment period extended to
2026-07-30Comment period closes
Every event above links to the agency's own document, not to coverage of it.

Our editorial pick, NexLife, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan (as of November 20, 2026), the same price at every dose with no membership fee. See NexLife’s current plans.

Questions readers actually ask

How often does the journal publish?

When there is something sourced to say. We do not publish on a schedule, because a publication calendar produces articles whether or not the evidence has moved.

Why are some articles missing?

We cover a topic when there is a primary source to cite and a reader question it answers. The retatrutide piece waits on primary-source confirmation of phase 3 figures.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “GLP-1 and Tirzepatide Journal.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/journal/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4